BioSpace News Archive

AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced results from an investigator-sponsored Phase Ib expansion cohort of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia (AML).

FEops, a leader in personalized predictive planning for structural heart interventions, today announced that FEops HEARTguideTM has received CE mark approval. FEops HEARTguideTM is a one-in-its-kind procedure planning environment for structural heart interventions that provides physicians unique insights to evaluate device sizing and positioning pre-operatively using novel computational modeling and simulation technology.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the H.C. Wainwright & Co. Global Life Sciences Conference in London, England on Monday, April 8th at 11:30am BST/6:30am ET/3:30am PT. Christopher C. LeMasters, Chief Business Officer, will provide a corporate update at the conference.

Johnson & Johnson (NYSE: JNJ) announced today that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash

Johnson & Johnson (NYSE: JNJ) today announced that it has completed the divestiture of its Advanced Sterilization Products (ASP) business, a division of Ethicon, Inc.*, to Fortive Corporation (NYSE: FTV) for an aggregate value of approximately $2.8 billion, consisting of $2.7 billion of cash proceeds from Fortive Corporation and $0.1 billion of retained net receivables.

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on its business.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Second Quarter Fiscal 2019 on Thursday, May 2, 2019, prior to the opening of trading on the New York Stock Exchange.

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 282,500 shares of common stock to be distributed among 10 new employees, with a grant date of April 1, 2019 (the “Inducement Grant”).

Seventeen patient groups representing millions of Americans with pre-existing conditions filed an amicus curiae (“friend-of-the-court”) brief today in the U.S. Court of Appeals for the Fifth Circuit in the case Texas v. United States, citing the devastating impact patients would face should the court uphold the District Court ruling to invalidate the Affordable Care Act (ACA).

Tomorrow on World Autism Awareness Day, The Center for Discovery will host a groundbreaking conference, “A New Landscape for Autism: The Science of Safe and Healing Environments.